Literature DB >> 14595115

Permissive roles of phosphatidyl inositol 3-kinase and Akt in skeletal myocyte maturation.

Elizabeth M Wilson1, Jolana Tureckova, Peter Rotwein.   

Abstract

Skeletal muscle differentiation, maturation, and regeneration are regulated by interactions between signaling pathways activated by hormones and growth factors, and intrinsic genetic programs controlled by myogenic transcription factors, including members of the MyoD and myocyte enhancer factor 2 (MEF2) families. Insulin-like growth factors (IGFs) play key roles in muscle development in the embryo, and in the maintenance and hypertrophy of mature muscle in the adult, but the precise signaling pathways responsible for these effects remain incompletely defined. To study mechanisms of IGF action in muscle, we have developed a mouse myoblast cell line termed C2BP5 that is dependent on activation of the IGF-I receptor and the phosphatidyl inositol 3-kinase (PI3-kinase)-Akt pathway for initiation of differentiation. Here, we show that differentiation of C2BP5 myoblasts could be induced in the absence of IGF action by recombinant adenoviruses expressing MyoD or myogenin, but it was reversibly impaired by the PI3-kinase inhibitor LY294002. Similar results were observed using a dominant-negative version of Akt, a key downstream component of PI3-kinase signaling, and also were seen in C3H 10T1/2 fibroblasts. Inhibition of PI3-kinase did not prevent accumulation of muscle differentiation-specific proteins (myogenin, troponin T, or myosin heavy chain), did not block transcriptional activation of E-box containing muscle reporter genes by MyoD or myogenin, and did not inhibit the expression or function of endogenous MEF2C or MEF2D. An adenovirus encoding active Akt could partially restore terminal differentiation of MyoD-expressing and LY294002-treated myoblasts, but the resultant myofibers contained fewer nuclei and were smaller and thinner than normal, indicating that another PI3-kinase-stimulated pathway in addition to Akt is required for full myocyte maturation. Our results support the idea that an IGF-regulated PI3-kinase pathway functions downstream of or in parallel with MyoD, myogenin, and MEF2 in muscle development to govern the late steps of differentiation that lead to multinucleated myotubes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595115      PMCID: PMC329222          DOI: 10.1091/mbc.e03-05-0351

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  49 in total

1.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.

Authors:  S C Bodine; T N Stitt; M Gonzalez; W O Kline; G L Stover; R Bauerlein; E Zlotchenko; A Scrimgeour; J C Lawrence; D J Glass; G D Yancopoulos
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

2.  CBP/p300 and muscle differentiation: no HAT, no muscle.

Authors:  A Polesskaya; I Naguibneva; L Fritsch; A Duquet; S Ait-Si-Ali; P Robin; A Vervisch; L L Pritchard; P Cole; A Harel-Bellan
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

3.  Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin.

Authors:  Lili Shu; Xiongwen Zhang; Peter J Houghton
Journal:  J Biol Chem       Date:  2002-03-01       Impact factor: 5.157

4.  Analysis of the myogenin promoter reveals an indirect pathway for positive autoregulation mediated by the muscle-specific enhancer factor MEF-2.

Authors:  D G Edmondson; T C Cheng; P Cserjesi; T Chakraborty; E N Olson
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

5.  Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth.

Authors:  Akihiro Takahashi; Yasuko Kureishi; Jiang Yang; Zhengyu Luo; Kun Guo; Debabrata Mukhopadhyay; Yuri Ivashchenko; Didier Branellec; Kenneth Walsh
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

6.  A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification.

Authors:  Giorgia Pallafacchina; Elisa Calabria; Antonio L Serrano; John M Kalhovde; Stefano Schiaffino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

7.  MyoD binds cooperatively to two sites in a target enhancer sequence: occupancy of two sites is required for activation.

Authors:  H Weintraub; R Davis; D Lockshon; A Lassar
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice.

Authors:  M E Coleman; F DeMayo; K C Yin; H M Lee; R Geske; C Montgomery; R J Schwartz
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

9.  Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice.

Authors:  Elisabeth R Barton; Linda Morris; Antonio Musaro; Nadia Rosenthal; H Lee Sweeney
Journal:  J Cell Biol       Date:  2002-04-01       Impact factor: 10.539

10.  Different modes of hypertrophy in skeletal muscle fibers.

Authors:  Angelika C Paul; Nadia Rosenthal
Journal:  J Cell Biol       Date:  2002-02-11       Impact factor: 10.539

View more
  28 in total

1.  An image analysis method for the precise selection and quantitation of fluorescently labeled cellular constituents: application to the measurement of human muscle cells in culture.

Authors:  Chibeza C Agley; Cristiana P Velloso; Norman R Lazarus; Stephen D R Harridge
Journal:  J Histochem Cytochem       Date:  2012-04-17       Impact factor: 2.479

2.  AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.

Authors:  Mathivanan Jothi; Kochi Nishijo; Charles Keller; Asoke K Mal
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

3.  MyoD synergizes with the E-protein HEB beta to induce myogenic differentiation.

Authors:  Maura H Parker; Robert L S Perry; Mélanie C Fauteux; Charlotte A Berkes; Michael A Rudnicki
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

4.  The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.

Authors:  Lili Shu; Peter J Houghton
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

5.  PTEN inhibition improves muscle regeneration in mice fed a high-fat diet.

Authors:  Zhaoyong Hu; Huiling Wang; In Hee Lee; Swati Modi; Xiaonan Wang; Jie Du; William E Mitch
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

Review 6.  Skeletal muscle hypertrophy and regeneration: interplay between the myogenic regulatory factors (MRFs) and insulin-like growth factors (IGFs) pathways.

Authors:  Nadège Zanou; Philippe Gailly
Journal:  Cell Mol Life Sci       Date:  2013-04-04       Impact factor: 9.261

7.  MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation.

Authors:  Eros Di Giorgio; Andrea Clocchiatti; Sara Piccinin; Andrea Sgorbissa; Giulia Viviani; Paolo Peruzzo; Salvatore Romeo; Sabrina Rossi; Angelo Paolo Dei Tos; Roberta Maestro; Claudio Brancolini
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

8.  Co-expression of IGF-1 family members with myogenic regulatory factors following acute damaging muscle-lengthening contractions in humans.

Authors:  Bryon R McKay; Ciara E O'Reilly; Stuart M Phillips; Mark A Tarnopolsky; Gianni Parise
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

9.  Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation.

Authors:  Peter Rotwein; Elizabeth M Wilson
Journal:  J Cell Physiol       Date:  2009-05       Impact factor: 6.384

10.  Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions.

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2008-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.